NASDAQ:ADXS

Advaxis Stock Forecast, Price & News

$0.52

-0.01 (-1.90 %)

(As of 06/11/2021 12:00 AM ET)

Add

Compare

Today's Range

$0.51

▼

$0.54

50-Day Range

$0.37

▼

$0.74

52-Week Range

$0.26

▼

$1.57

Volume4.47 million shs

Average Volume19.64 million shs

Market Capitalization$71.13 million

P/E RatioN/A

Dividend YieldN/A

Beta2.4

30 days | 90 days | 365 days | Advanced Chart

Receive ADXS News and Ratings via Email

Sign-up to receive the latest news and ratings for Advaxis and its competitors with MarketBeat's FREE daily newsletter.

About Advaxis

Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.

Advaxis (NASDAQ:ADXS) Shares Cross Above 200-Day Moving Average of $0.00
June 12, 2021 | americanbankingnews.com

Advaxis (NASDAQ:ADXS) Stock Crosses Above Two Hundred Day Moving Average of $0.00
June 3, 2021 | americanbankingnews.com

Curative Biotechnology, Inc. Files 2021 First Quarter Financials and Issues Letter to Shareholders - StreetInsider.com
May 25, 2021 | streetinsider.com

Advaxis Stock Gives Every Indication Of Being Significantly Overvalued - Yahoo Finance
May 21, 2021 | finance.yahoo.com

Pre-Open Stock Movers 05/20: (SPCE) (VTGN) (PLCE) Higher; (BDTX) (RIDE) (BJ) Lower (more...) - StreetInsider.com
May 20, 2021 | streetinsider.com

Advaxis' ADXS-503 Shows Durable Benefit Beyond One Year in Lung Cancer Patients Progressing on Merck's Keytruda - Benzinga
May 20, 2021 | benzinga.com

Advaxis updates early stage results for off-the-shelf immunotherapy with Keytruda in lung cancer - Seeking Alpha
May 20, 2021 | seekingalpha.com

Advaxis Presents Updated Clinical Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC - GlobeNewswire
May 20, 2021 | globenewswire.com

Advaxis Presents Updated Clinical Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting - Yahoo Finance
May 19, 2021 | finance.yahoo.com

Advaxis Presents Updated Clinical Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
May 19, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADXS
Previous Symbol
CUSIPN/A
CIK1100397
Webwww.advaxis.com
Phone609-452-9813
Employees17
Year FoundedN/A

Sales & Book Value

Annual Sales$250,000.00
Price / Sales284.53
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.39 per share
Price / Book1.32

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares137,960,000
Market Cap$71.13 million
Next Earnings Date9/8/2021 (Estimated)
OptionableOptionable

MarketRank^™

Overall MarketRank^™

1.18 out of 5 stars

Medical Sector

980th out of 2,099 stocks

Pharmaceutical Preparations Industry

482nd out of 831 stocks

3.5 Analyst's Opinion

Consensus Rating
Advaxis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $2.25, Advaxis has a forecasted upside of 336.4% from its current price of $0.52.
Amount of Analyst Coverage
Advaxis has only been the subject of 1 research reports in the past 90 days.

2.4 Community Rank

Outperform Votes
Advaxis has received 368 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Advaxis has received 407 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Advaxis has received 52.52% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Advaxis and other stocks. Vote “Outperform” if you believe ADXS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ADXS will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Advaxis does not currently pay a dividend.
Dividend Growth
Advaxis does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Advaxis insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.26% of the stock of Advaxis is held by insiders.
Percentage Held by Institutions
Only 7.52% of the stock of Advaxis is held by institutions.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Advaxis is -1.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Advaxis is -1.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Advaxis has a P/B Ratio of 1.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Advaxis (NASDAQ:ADXS) Frequently Asked Questions

Is Advaxis a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Advaxis in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Advaxis stock.
View analyst ratings for Advaxis or view top-rated stocks.

What stocks does MarketBeat like better than Advaxis?

Wall Street analysts have given Advaxis a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Advaxis wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Advaxis?

Advaxis saw a increase in short interest during the month of May. As of May 28th, there was short interest totaling 5,750,000 shares, an increase of 70.6% from the May 13th total of 3,370,000 shares. Based on an average trading volume of 9,910,000 shares, the short-interest ratio is currently 0.6 days. Approximately 4.3% of the company's shares are short sold.
View Advaxis' Short Interest.

When is Advaxis' next earnings date?

Advaxis is scheduled to release its next quarterly earnings announcement on Wednesday, September 8th 2021.
View our earnings forecast for Advaxis.

How were Advaxis' earnings last quarter?

Advaxis, Inc. (NASDAQ:ADXS) issued its quarterly earnings data on Tuesday, March, 16th. The biotechnology company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.10. The biotechnology company earned $1.62 million during the quarter.
View Advaxis' earnings history.

How has Advaxis' stock been impacted by COVID-19?

Advaxis' stock was trading at $0.6666 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ADXS stock has decreased by 22.7% and is now trading at $0.5156.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for ADXS?

1 equities research analysts have issued 1 year price targets for Advaxis' shares. Their forecasts range from $2.25 to $2.25. On average, they expect Advaxis' share price to reach $2.25 in the next year. This suggests a possible upside of 336.4% from the stock's current price.
View analysts' price targets for Advaxis or view top-rated stocks among Wall Street analysts.

Who are Advaxis' key executives?

Advaxis' management team includes the following people:

Mr. Kenneth A. Berlin J.D., Pres, Interim CFO, CEO & Director (Age 57, Pay $1.16M)
Dr. Andres A. Gutierrez, Exec. VP & Chief Medical Officer (Age 60, Pay $624.26k)
Mr. Igor Gitelman CPA, M.B.A., CPA, MBA, Chief Accounting Officer & VP of Fin. (Age 45)

Who are some of Advaxis' key competitors?

Some companies that are related to Advaxis include Spruce Biosciences (SPRB), Clever Leaves (CLVR), PDS Biotechnology (PDSB), BELLUS Health (BLU), Kezar Life Sciences (KZR), Corbus Pharmaceuticals (CRBP), Theratechnologies (THERF), Oncternal Therapeutics (ONCT), Jaguar Health (JAGX), Kamada (KMDA), Xeris Pharmaceuticals (XERS), Seelos Therapeutics (SEEL), Hookipa Pharma (HOOK), Marker Therapeutics (MRKR) and AVEO Pharmaceuticals (AVEO).
View all of ADXS's competitors.

What other stocks do shareholders of Advaxis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Advaxis investors own include Inovio Pharmaceuticals (INO), Madrigal Pharmaceuticals (MDGL), Merck & Co., Inc. (MRK), Anavex Life Sciences (AVXL), VistaGen Therapeutics (VTGN), Novavax (NVAX), (CELG), Highpower International (HPJ), OPKO Health (OPK) and Athersys (ATHX).

What is Advaxis' stock symbol?

Advaxis trades on the NASDAQ under the ticker symbol "ADXS."

Who are Advaxis' major shareholders?

Advaxis' stock is owned by many different institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (1.88%), BlackRock Inc. (0.97%), Geode Capital Management LLC (0.53%), Citadel Advisors LLC (0.30%), Price T Rowe Associates Inc. MD (0.12%) and Goldman Sachs Group Inc. (0.06%).
View institutional ownership trends for Advaxis.

Which major investors are selling Advaxis stock?

ADXS stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, and Price T Rowe Associates Inc. MD.
View insider buying and selling activity for Advaxis or view top insider-selling stocks.

Which major investors are buying Advaxis stock?

ADXS stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Citadel Advisors LLC, Geode Capital Management LLC, Goldman Sachs Group Inc., Bank of New York Mellon Corp, and Morgan Stanley.
View insider buying and selling activity for Advaxis or or view top insider-buying stocks.

How do I buy shares of Advaxis?

Shares of ADXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Advaxis' stock price today?

One share of ADXS stock can currently be purchased for approximately $0.52.

How much money does Advaxis make?

Advaxis has a market capitalization of $71.13 million and generates $250,000.00 in revenue each year.

How many employees does Advaxis have?

Advaxis employs 17 workers across the globe.

What is Advaxis' official website?

The official website for Advaxis is www.advaxis.com.

Where are Advaxis' headquarters?

Advaxis is headquartered at 305 COLLEGE ROAD EAST, PRINCETON NJ, 08540.

How can I contact Advaxis?

Advaxis' mailing address is 305 COLLEGE ROAD EAST, PRINCETON NJ, 08540. The biotechnology company can be reached via phone at 609-452-9813 or via email at [email protected]

This page was last updated on 6/13/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here